# GRAIL, Inc. (GRAL) > Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/grail-inc/ JSON: https://steadybase.io/company/grail-inc.json Checked Nov 10, 2026. Latest filing read: Nov 5, 2026. ## Company - Legal name: GRAIL, Inc. - Ticker: GRAL (Nasdaq) - SEC CIK: 0001699031 - Industry: Services-Medical Laboratories (SIC 8071) - Headquarters: Sunnyvale, CA - Fiscal year ends: December 31 - SEC filer category: Non-accelerated filer
Emerging growth company - Website: grail.com - LinkedIn: https://www.linkedin.com/company/grail-inc. - Next earnings date: Nov 11, 2026 ## Key facts - Revenue: $147.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/0001628280-26-017319-index.html - Operating income: -$562.2M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/0001628280-26-017319-index.html - Net income: -$408.4M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/0001628280-26-017319-index.html - SG&A: $275.8M for the fiscal year ended Dec 31, 2025 (10-K filed Mar 12, 2026). Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/0001628280-26-017319-index.html - Employees: 910 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm - Shares outstanding: 44,962,171 as of Nov 2, 2026 (10-Q filed Nov 5, 2026). Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026071041/0001628280-26-071041-index.html - Auditor: Ernst & Young LLP, San Mateo, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm ## Business We are an innovative commercial-stage healthcare company focused on shifting the paradigm in early cancer detection at population scale. We believe screening individuals for many types of cancer with a single test represents a significant opportunity to reduce the global burden of cancer. Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm ## Annual results | Fiscal year ended | Revenue | Operating income | Net income | SG&A | |---|---|---|---|---| | Dec 31, 2025 | $147.2M | -$562.2M | -$408.4M | $275.8M | | Dec 31, 2024 | $125.6M | -$2.2B | -$2.0B | $367.8M | | Dec 31, 2023 | $93.1M | -$1.5B | -$1.5B | $362.6M | | Jan 1, 2023 | $55.5M | -$5.4B | -$5.4B | $296.4M | Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/grail-inc.json ## Officers and directors - Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026070118/ex9912026q3earningspressre.htm - Joshua J. Ofman, Chief Executive Officer. Source: Form 4 filed Sep 23, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026063233/0001628280-26-063233-index.htm - Robert P. Ragusa, Chief Executive Officer. Source: Form 4 filed Apr 9, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026024550/0001628280-26-024550-index.htm - Aaron Freidin, Chief Financial Officer. LinkedIn: https://linkedin.com/in/aaron-freidin-100b7413. Source: Form 4 filed Sep 23, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026063234/0001628280-26-063234-index.htm - Andrew John Partridge, Chief Growth Officer. Source: Form 4 filed Jun 5, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026041356/0001628280-26-041356-index.htm - Gregory (Greg) Summe, Director and Chairperson of the Board. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm - Sarah Krevans, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm - Steve Mizell, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm - Steven Mizell, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm - William Chase, Director. Source: 10-K filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm - Gregory Summe, Board member (per proxy). Source: DEF 14A filed Apr 28, 2026, https://www.sec.gov/Archives/edgar/data/1699031/000162828026027946/gral-20260428.htm ## Recent 8-K events - Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026070118/gral-20261104.htm - Aug 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/gral-20260805.htm - Jun 22, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026044693/gral-20260618.htm - Jun 1, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/gral-20260601.htm - May 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026030495/gral-20260505.htm - Feb 19, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000169903126000009/gral-20260219.htm - Jan 12, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026001786/gral-20260112.htm - Nov 14, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828025052184/gral-20251113.htm - Nov 12, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000169903125000189/gral-20251112.htm - Oct 20, 2025: Item 1.01, Entry into a material definitive agreement; Item 3.02, Unregistered sales of equity securities; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828025045532/gral-20251018.htm ## Insider trades (Form 4) - Oct 15, 2026: Joshua J. Ofman (Chief Executive Officer) sold 20,000 shares, about $2.7M. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026066148/0001628280-26-066148-index.htm - Oct 5, 2026: Andrew John Partridge (Chief Growth Officer) sold 7,873 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026065365/0001628280-26-065365-index.htm - Oct 5, 2026: Aaron Freidin (Chief Financial Officer) sold 23,619 shares, about $3.5M. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026065364/0001628280-26-065364-index.htm - Sep 21, 2026: Aaron Freidin (Chief Financial Officer) sold 4,100 shares, about $382,682. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026063234/0001628280-26-063234-index.htm - Sep 21, 2026: Joshua J. Ofman (Chief Executive Officer) sold 61,452 shares, about $6.0M. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026063233/0001628280-26-063233-index.htm - Aug 27, 2026: Joshua J. Ofman (Chief Executive Officer) sold 5,000 shares, about $425,100. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026059682/0001628280-26-059682-index.htm - Aug 27, 2026: Aaron Freidin (Chief Financial Officer) sold 7,900 shares, about $671,579. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026059681/0001628280-26-059681-index.htm - Jun 4, 2026: Andrew John Partridge (Chief Growth Officer) sold 1,491 shares, about $91,070. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026041356/0001628280-26-041356-index.htm - Apr 8, 2026: Aaron Freidin (Chief Financial Officer) sold 45,806 shares, about $2.3M. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026024551/0001628280-26-024551-index.htm - Apr 8, 2026: Robert P. Ragusa (Chief Executive Officer) sold 123,502 shares, about $6.2M. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026024550/0001628280-26-024550-index.htm - Apr 8, 2026: Joshua J. Ofman (President) sold 61,665 shares, about $3.1M. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026024549/0001628280-26-024549-index.htm - Mar 9, 2026: Aaron Freidin (Chief Financial Officer) sold 3,147 shares, about $154,062. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026016218/0001628280-26-016218-index.htm - Mar 9, 2026: Joshua J. Ofman (President) sold 3,627 shares, about $177,227. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026016217/0001628280-26-016217-index.htm - Mar 9, 2026: Robert P. Ragusa (Chief Executive Officer) sold 8,441 shares, about $409,246. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026016216/0001628280-26-016216-index.htm - Mar 2, 2026: Joshua J. Ofman (President) sold 17,002 shares, about $852,923. Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026014344/0001628280-26-014344-index.htm ## What management said - "GRAIL achieved significant milestones this quarter including a favorable vote for approval of Galleri at the FDA Advisory Committee" Josh Ofman, MD, MSHS, Chief Executive Officer of GRAIL (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1699031/000162828026070118/ex9912026q3earningspressre.htm ## Latest filings - 8-K filed Aug 5, 2026: https://www.sec.gov/Archives/edgar/data/1699031/000162828026053341/gral-20260805.htm - 10-K filed Mar 12, 2026: https://www.sec.gov/Archives/edgar/data/1699031/000162828026017319/gral-20251231.htm - 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1699031/000162828026054307/gral-20260630.htm - DEF 14A filed Apr 28, 2026: https://www.sec.gov/Archives/edgar/data/1699031/000162828026027946/gral-20260428.htm ## About this data SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from. Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/